Aluminium glycinate (ATC A02AB07)

toxylact: a02ab07 aluminium glycinate

The first professional lActological database in the word

Aluminium glycinate (ATC A02AB07) is generally considered compatible with breastfeeding, because aluminium antacids are poorly absorbed from the maternal gut and only very small amounts, if any, are expected to reach breast milk or the infant.

Overview of aluminium glycinate

Aluminium glycinate (dihydroxyaluminium aminoacetate) is an antacid used to relieve heartburn, dyspepsia, gastro‑oesophageal reflux and as adjuvant therapy in peptic ulcer disease. Like other aluminium-containing antacids, it acts locally in the stomach by neutralising gastric acid and does not require systemic absorption to exert its therapeutic effect.

Transfer into breast milk

Aluminium from antacids has very low oral bioavailability, so only small fractions are absorbed into maternal systemic circulation. Aluminium and magnesium are naturally present in breast milk and infant foods, and available data indicate that maternal use of aluminium antacids does not significantly increase aluminium levels in breast milk. Clinical experience and expert reviews therefore conclude that antacids, including aluminium salts, are acceptable during lactation with no need for specific precautions.

Potential effects on the breastfed infant

Because exposure from maternal aluminium glycinate is expected to be minimal, clinically relevant toxicity in breastfed infants is unlikely. Expert sources report extensive experience with aluminium-containing antacids during breastfeeding without documented adverse effects in infants, and no routine infant monitoring is recommended when these drugs are used at standard doses. As with any maternal medication, clinicians may advise observation for non‑specific gastrointestinal symptoms (changes in stool pattern, irritability), although such reactions are not well documented for aluminium antacids.

Maternal considerations during lactation

Antacids are considered first‑line pharmacological options for heartburn and dyspepsia in breastfeeding women, after lifestyle and dietary measures. Treatment with aluminium-containing antacids, including aluminium glycinate, should follow general principles: use the lowest effective dose, limit the duration to symptom control, and avoid chronic high-dose aluminium exposure in women with significant renal impairment. If symptoms persist or long-term acid suppression is needed, H2-receptor antagonists or proton pump inhibitors with evidence of safety in lactation may be considered as alternatives.

Risk assessment and professional recommendations

Current lactation references and national medicines advisory services state that antacids and alginates are compatible with breastfeeding and are preferred over systemically absorbed alternatives for short-term dyspepsia management. Aluminium hydroxide is explicitly listed as a preferred antacid during breastfeeding, and aluminium glycinate is expected to share a similar safety profile based on its pharmacology and route of action. Overall, when clinically indicated and used as directed, aluminium glycinate can be considered a low‑risk option for treating gastric acidity in lactating women.

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.